Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS

NCT01450280 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Oxford